Immuneering Corporation

NASDAQ•IMRX

CEO: Dr. Benjamin J. Zeskind M.B.A., Ph.D.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2021-07-30

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Contact Information

245 Main Street, Second Floor, Cambridge, MA, 02142, United States

617-500-8080

immuneering.com

Market Cap

$174.25M

P/E (TTM)

-3.8

17.2

Dividend Yield

52W High

$10.08

52W Low

$1.10

52W Range

41%

Rank44Top 53.8%

3.7

F-Score

Modified Piotroski Analysis

Based on 6-year fundamentals

Weak • 3.7 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2020-2025

Financial Dashboard

Q4 2025 Data

Revenue

$0.00+0.00%

4-Quarter Trend

EPS

-$0.18+0.00%

4-Quarter Trend

FCF

-$9.96M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Net Loss Decreased Net loss $56.0M for 2025, an 8.2% reduction compared to $61.0M loss reported in 2024.

R&D Spending Reduced Total R&D expenses fell 12.3% to $42.0M in 2025, driven by pausing envometinib program development efforts.

Significant Capital Raised Financing activities provided $226.6M cash, reflecting multiple private placements and public equity offerings during 2025.

Cash Runway Extended Cash reserves $128.6M as of year-end, sufficient to fund operations and development activities into 2029.

Risk Factors

Late-Stage Clinical Dependency Business substantially dependent on successful atebimetinib development; no products approved for commercial sale currently.

Substantial Capital Needs Requires substantial additional capital to finance operations; failure to raise funds delays or eliminates development programs.

Regulatory Approval Unpredictable Regulatory approval processes are lengthy, time-consuming, and inherently unpredictable regarding outcomes for candidates.

Platform Technology Reliance Business substantially dependent on proprietary platform and information technology systems; failure materially harms operations.

Outlook

Phase 3 Trial Dosing Planned Expect dosing first patient in atebimetinib Phase 3 MAPKeeper 301 trial in mid-2026 for pancreatic cancer indication.

Atebimetinib Data Updates Announce further updated survival data from over 50 first-line pancreatic cancer patients in first half of 2026.

New Combination Trial Dosing Dosing first patient in planned atebimetinib combination trial with Libtayo in NSCLC patients second half 2026.

Envometinib Partnership Focus Paused internal advancement of envometinib; pursuing partnership opportunities and considering other developmental paths.

Peer Comparison

Revenue (TTM)

ARCT

$74.12M

-46.4%

CDXS

$70.39M

+18.6%

ENTA

$66.98M

+0.6%

Gross Margin (Latest Quarter)

ENTA

100.0%

+0.0pp

ASMB

100.0%

+0.0pp

SGMO

100.0%

+0.0pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
SLS	$717.91M	-21.1	-95.2%	1.2%
TRDA	$482.00M	-3.6	-39.8%	13.5%
ASMB	$451.26M	-5.7	-59.0%	1.1%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

N/M

Revenue Volatile

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:Mar 19, 2026

EPS:-$0.31

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data